CFM
IMMX icon

Compass Financial Management’s Immix Biopharma IMMX Stock Holding History

Compass Financial Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56K Buy
+6,000
New +$55.7K 0.01% 671

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Compass Financial Management's IMMX Position: Q2 2026 in Review

Compass Financial Management opened a new position in Immix Biopharma (IMMX) in Q2 2026: 6,000 shares worth $56K. The stake represents 0.01% of the portfolio and ranks #671 among its holdings.

101 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Compass Financial Management held 6,000 shares of Immix Biopharma worth $56K as of Q2 2026.
  • Immix Biopharma was a new Compass Financial Management position in Q2 2026.
  • Immix Biopharma made up 0.01% of Compass Financial Management's portfolio in Q2 2026, its #671 holding.
  • 101 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Compass Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.